Molecular Templates, Inc. (MTEM)
OTCMKTS
· Delayed Price · Currency is USD
0.0003
0.00 (0.00%)
Jan 31, 2025, 4:00 PM EST
Molecular Templates Revenue
Molecular Templates had revenue of $572.00K in the quarter ending June 30, 2024, a decrease of -91.67%. This brings the company's revenue in the last twelve months to $25.47M, down -49.41% year-over-year. In the year 2023, Molecular Templates had annual revenue of $57.31M with 190.10% growth.
Revenue (ttm)
25.47M
Revenue Growth
-49.41%
P/S Ratio
0.00
Revenue / Employee
410.81K
Employees
62
Market Cap
1.98K
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.79B |
SS Innovations International | 16.04M |
Veradigm | 1.53B |
Elite Pharmaceuticals | 71.17M |
Glass House Brands | 188.29M |
Northwest Biotherapeutics | 1.60M |
BioStem Technologies | 210.49M |
Silence Therapeutics | 21.77M |
Molecular Templates News
- 6 weeks ago - Why Molecular Templates (MTEM) Stock Is Down 60% - Benzinga
- 6 weeks ago - Molecular Templates shares tumble on Nasdaq delisting - Seeking Alpha
- 6 weeks ago - Molecular Templates Announces Notice of Delisting and Failure to Satisfy Continued Listing Rules - GlobeNewsWire
- 2 months ago - Molecular Templates Announces Receipt of Expected Notification of Deficiency from Nasdaq Related to Delayed filing of Quarterly Report on Form 10-Q and Failure to Meet Bid Price Requirements - GlobeNewsWire
- 6 months ago - Molecular Templates, Inc. Reports Second Quarter 2024 Financial Results and Corporate Update - GlobeNewsWire
- 8 months ago - Molecular Templates, Inc. Provides Interim Update - GlobeNewsWire
- 9 months ago - Molecular Templates, Inc. Reports First Quarter 2024 Financial Results and Corporate Update - GlobeNewsWire
- 10 months ago - Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patie - GlobeNewsWire